Efficient synthetic inhibitors of anthrax lethal factor

Inhalation anthrax is a deadly disease for which there is currently no effective treatment. Bacillus anthracis lethal factor (LF) metalloproteinase is an integral component of the tripartite anthrax lethal toxin that is essential for the onset and progression of anthrax. The authors report here on a fragment-based approach that allowed us to develop inhibitors of LF. The small-mol. inhibitors the authors have designed, synthesized, and tested are highly potent and selective against LF in both in vitro tests and cell-based assays. These inhibitors do not affect the prototype human metalloproteinases that are structurally similar to LF. Initial in vivo evaluation of postexposure efficacy of our inhibitors combined with antibiotic ciprofloxacin against B. anthracis resulted in significant protection. Our data strongly indicate that the scaffold of inhibitors the authors have identified is the foundation for the development of novel, safe, and effective emergency therapy of postexposure inhalation anthrax.